- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
Anthera Pharmaceuticals (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency. As quoted in the press release: “The positive interim futility analysis of the RESULT study represents one of the last clinical milestones ahead of …
Anthera Pharmaceuticals (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency.
As quoted in the press release:
“The positive interim futility analysis of the RESULT study represents one of the last clinical milestones ahead of topline data this quarter,” shared Craig Thompson, President & CEO of Anthera. “We look forward to sharing the study outcome shortly and potentially providing patients with a new treatment option for their exocrine pancreatic insufficiency therapy.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.